Vir Biotechnology (VIR) News Today $7.03 -0.98 (-12.23%) (As of 11/18/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational ProgramNovember 18 at 9:15 PM | businesswire.comVir Biotechnology (VIR) Gets a Buy from BarclaysNovember 18 at 6:27 PM | markets.businessinsider.comVir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines AgencyNovember 18 at 4:05 PM | businesswire.comVir Biotechnology: Promising Hepatitis B Treatment Data Amid Cautious Optimism and Awaited MilestonesNovember 17 at 4:32 PM | markets.businessinsider.comVir Biotechnology (NASDAQ:VIR) Stock, Insider Trading ActivityNovember 16 at 1:49 PM | benzinga.comWhat's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?November 15, 2024 | finance.yahoo.comVir Biotechnology (NASDAQ:VIR) Stock Price Down 7.4% - Here's WhyVir Biotechnology (NASDAQ:VIR) Stock Price Down 7.4% - Here's WhyNovember 15, 2024 | marketbeat.comVir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver MeetingNovember 15, 2024 | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 39.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,383,029 shares of the coNovember 13, 2024 | marketbeat.comHold Recommendation for Vir Biotechnology Amid Cautious Optimism on Infectious Disease and Oncology ProspectsNovember 9, 2024 | markets.businessinsider.comVir Biotechnology participates in a conference call with JPMorganNovember 6, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Vir Biotechnology (VIR) and Moderna (MRNA)November 6, 2024 | markets.businessinsider.comFY2024 EPS Estimate for Vir Biotechnology Lowered by AnalystVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Analysts at HC Wainwright dropped their FY2024 earnings estimates for Vir Biotechnology in a report issued on Monday, November 4th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($3.70) per share for the yNovember 6, 2024 | marketbeat.comLeerink Partnrs Has Negative Outlook of VIR FY2024 EarningsVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for Vir Biotechnology in a research note issued on Sunday, November 3rd. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($4.02) per share for the yeNovember 6, 2024 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De Sells 1,403 SharesNovember 6, 2024 | insidertrades.comVir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay OffNovember 5, 2024 | seekingalpha.comVir Biotechnology price target lowered to $26 from $28 at BarclaysNovember 4, 2024 | markets.businessinsider.comVir Biotechnology’s Promising Hepatitis Programs and Strategic FDA Alignment Justify Buy RatingNovember 4, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)HC Wainwright reiterated a "buy" rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Monday.November 4, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Given New $26.00 Price Target at BarclaysBarclays reduced their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Monday.November 4, 2024 | marketbeat.comAnalysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest ResultsNovember 4, 2024 | finance.yahoo.comVir Biotechnology Third Quarter 2024 Earnings: Misses ExpectationsNovember 2, 2024 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | msn.comBank of America Securities Sticks to Their Hold Rating for Vir Biotechnology (VIR)November 2, 2024 | markets.businessinsider.comVir Biotechnology Reports Q3 2024 Financial ResultsNovember 1, 2024 | markets.businessinsider.comVir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years agoNovember 1, 2024 | finance.yahoo.comVir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...November 1, 2024 | finance.yahoo.comCautious Optimism for Vir Biotechnology: Hold Rating Amid Promising yet Uncertain Hepatitis Program DevelopmentsNovember 1, 2024 | markets.businessinsider.comVir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial UpdatesNovember 1, 2024 | marketwatch.comVir Biotechnology (NASDAQ:VIR) Announces Quarterly Earnings ResultsVir Biotechnology (NASDAQ:VIR - Get Free Report) issued its earnings results on Thursday. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.60). Vir Biotechnology had a negative return on equity of 30.93% and a negative net margin of 612.40%. The business had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. During the same period in the previous year, the firm posted ($1.22) EPS. The firm's revenue was down 9.8% compared to the same quarter last year.November 1, 2024 | marketbeat.comInvestors Purchase Large Volume of Call Options on Vir Biotechnology (NASDAQ:VIR)Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) saw some unusual options trading on Friday. Stock traders bought 6,039 call options on the company. This represents an increase of 3,651% compared to the typical volume of 161 call options.November 1, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Down on Disappointing EarningsVir Biotechnology (NASDAQ:VIR) Shares Gap Down After Earnings MissNovember 1, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a research report on Friday.November 1, 2024 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Vir Biotechnology (VIR)November 1, 2024 | markets.businessinsider.comVir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateOctober 31, 2024 | finance.yahoo.comWhat's Next: Vir Biotechnology's Earnings PreviewOctober 31, 2024 | benzinga.comVir Biotechnology (VIR) Scheduled to Post Earnings on ThursdayVir Biotechnology (NASDAQ:VIR) will be releasing earnings after the market closes on Thursday, October 31, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=637083)October 24, 2024 | marketbeat.comState Street Corp's Strategic Acquisition in Vir Biotechnology IncOctober 19, 2024 | finance.yahoo.comVir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024October 15, 2024 | finance.yahoo.comVir Biotechnology, Inc.October 12, 2024 | edition.cnn.comMillennium Management LLC Purchases 606,804 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)Millennium Management LLC grew its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 94.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,248,131 shares of the company's stock after buying anOctober 8, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comVir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the companyOctober 5, 2024 | finance.yahoo.comQ3 pharma and biotech layoffs in charts: More than 1000 each in July and AugustOctober 4, 2024 | msn.comAlgert Global LLC Purchases New Position in Vir Biotechnology, Inc. (NASDAQ:VIR)Algert Global LLC purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 166,835 shares of the company's stock, valued at approximOctober 4, 2024 | marketbeat.comVir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual ConferenceOctober 3, 2024 | stockhouse.comCubist Systematic Strategies LLC Grows Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Cubist Systematic Strategies LLC boosted its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 6,402.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 188,624 shares of the company's stock after purchasing an additional 185,723October 2, 2024 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Sets New 12-Month Low at $7.13Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week Low at $7.13October 1, 2024 | marketbeat.com200,000 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Affinity Asset Advisors LLCAffinity Asset Advisors LLC acquired a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 200,000 shares of the company's stock, valuedSeptember 25, 2024 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Stock Position Raised by Federated Hermes Inc.Federated Hermes Inc. boosted its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 19,327.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 300,148 shares of the company's stock after purchasing aSeptember 20, 2024 | marketbeat.com Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address 2024 Election Year Stocks: Uncover Hidden Gems! (Ad)In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss. Secure your copy now by clicking this link. VIR Media Mentions By Week VIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼0.830.56▲Average Medical News Sentiment VIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼84▲VIR Articles Average Week Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FATE News BLUE News CRSP News IMVT News DNLI News IBRX News KYMR News SWTX News VCEL News IOVA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 11/19/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIR Stock Alerts